CBP-501

CBP-501, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser216-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC50 values of 0.9 μM, 1.4 μM 3.4 μM and 6.5 μM, respectively. CBP-501 is used for various types of cancer[1][2].

Product Specifications

CAS Number

[565434-85-7]

UNSPSC

12352209

Target

Calmodulin; Checkpoint Kinase (Chk) ; MAP3K; MAPKAPK2 (MK2)

Type

Peptides

Related Pathways

Cell Cycle/DNA Damage; MAPK/ERK Pathway; Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cbp-501.html

Purity

99.75

Smiles

N=C(N)NCCC[C@H](C(O)=O)NC([C@@H](CCCNC(N)=N)NC([C@@H](CCC(N)=O)NC([C@@H](CCCNC(N)=N)NC([C@@H](CCCNC(N)=N)NC([C@@H](CCCNC(N)=N)NC([C@@H](CC1CCCCC1)NC([C@@H](CC2=C(F)C(F)=C(F)C(F)=C2F)NC([C@@H](CO)NC([C@@H](CC3=CNC4=CC=CC=C34)NC([C@@H](CO)NC([C@@H](CC5=CC=C(C(C6=CC=CC=C6)=O)C=C5)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C86H122F5N29O17

Molecular Weight

1929.06

References & Citations

[1]Enzler T, et al. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma. Eur J Cancer. 2024 Apr;201:113950.|[2]Shi-Ken Sha, et al. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. Mol Cancer Ther. 2007 Jan;6 (1) :147-53.